Determinants of COVID-19 vaccine-induced myocarditis
Background: Following the roll-out of the Pfizer-BioNTech BNT162b2, Moderna mRNA-1273, and Janssen Ad26.COV2.S coronavirus disease 2019 (COVID-19) injections in the United States, millions of individuals have reported adverse events (AEs) using the vaccine adverse events reports system (VAERS). The...
Main Authors: | Jessica Rose, Nicolas Hulscher, Peter A. McCullough |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2024-01-01
|
Series: | Therapeutic Advances in Drug Safety |
Online Access: | https://doi.org/10.1177/20420986241226566 |
Similar Items
-
Immune Checkpoint Inhibitor-Induced Myocarditis vs. COVID-19 Vaccine-Induced Myocarditis—Same or Different?
by: Lior Zornitzki, et al.
Published: (2022-09-01) -
Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology
by: Kamron Reza Hamedi, et al.
Published: (2023-02-01) -
Myocarditis in children after COVID-19 vaccine
by: Othman A Aljohani, et al.
Published: (2022-01-01) -
Remarks on Myocarditis Associated with COVID-19 Infection and Myocarditis Following mRNA COVID-19 Vaccination
by: Andrea Frustaci
Published: (2022-11-01) -
Myocarditis and COVID-19 mRNA vaccination
by: Rujittika Mungmunpuntipantip, et al.
Published: (2022-08-01)